Inhibitor Therapeutics' Losses Widen Amid R&D Spend, Cash Dwindles

TL;DR

**INTI is burning cash fast with no revenue, betting big on a regulatory shortcut for its BCCNS drug – high risk, high reward.**

AI Summary

Inhibitor Therapeutics, Inc. (INTI) reported a net loss of $1,292,788 for the six months ended June 30, 2025, an increase from a net loss of $1,186,401 for the same period in 2024. The company generated no revenue in either period. Research and development expenses increased to $561,681 for the six months ended June 30, 2025, up from $500,135 in the prior year, reflecting ongoing drug formulation efforts with Avior Bio, Inc. General and administrative expenses decreased slightly to $808,643 from $859,829. Cash and cash equivalents significantly declined to $3,737,903 as of June 30, 2025, from $5,606,863 at December 31, 2024. The company continues to focus on developing itraconazole for basal cell carcinoma (BCC), prostate, and lung cancers, and has engaged Avior Bio, Inc. to create a novel formulation. INTI expects its current cash to be sufficient for the foreseeable future to pursue FDA processes for its BCCNS product without further clinical trials, but acknowledges no assurance of success in raising additional capital if needed.

Why It Matters

Inhibitor Therapeutics' widening net loss and declining cash position are critical for investors, signaling increased burn rate without a clear path to revenue. The company's strategy hinges on a novel itraconazole formulation and FDA approval for BCCNS without new clinical trials, a high-risk proposition in the competitive pharmaceutical development landscape. Success could offer a significant return, but failure to secure FDA approval or additional funding would severely impact employees, future product development, and market confidence. This financial health directly affects INTI's ability to compete with larger, better-funded biopharmaceutical companies.

Risk Assessment

Risk Level: high — The company reported a net loss of $1,292,788 for the six months ended June 30, 2025, and has no ongoing source of revenue. Cash and cash equivalents decreased by $1,868,960 in the first six months of 2025, leaving only $3,737,903. This significant cash burn, coupled with reliance on a single product strategy and the uncertainty of FDA approval without additional clinical trials, indicates a high financial and operational risk.

Analyst Insight

Investors should exercise extreme caution and consider this a highly speculative investment. Monitor INTI's progress with the FDA's Rare Disease Endpoint Advancement (RDEA) pilot program and the pharmacokinetic crossover study results with Avior Bio, Inc. closely. Any delays or negative outcomes in these areas could severely impact the company's viability and stock price.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$1,292,788

eps

N/A

gross Margin

N/A

cash Position

$3,737,903

revenue Growth

N/A

Key Numbers

• $1.29M — Net Loss (Increased from $1.19M in prior year, indicating widening losses.)
• $3.74M — Cash and Cash Equivalents (Decreased from $5.61M at year-end 2024, showing significant cash burn.)
• $561.7K — Research and Development Expenses (Increased from $500.1K, reflecting ongoing drug development costs.)
• $3.0M — Deferred Revenue (Represents royalties advanced by Mayne Pharma, classified as non-current.)
• 172,573,545 — Common Stock Shares Outstanding (As of June 30, 2025, reflecting minor dilution from equity incentive plan.)

Key Players & Entities

• Inhibitor Therapeutics, Inc. (company) — registrant
• Johns Hopkins University (company) — licensor of patent rights
• Avior Bio, Inc. (company) — developer of novel itraconazole formulation
• Niraj Vasisht (person) — President and Chairman of the Board of Avior Bio, Inc. and INTI Board Member
• U.S Food and Drug Administration (regulator) — regulatory body for drug approval
• Mayne Pharma Ventures Pty Ltd. (company) — advanced $3 million in royalties
• $1,292,788 (dollar_amount) — net loss for six months ended June 30, 2025
• $3,737,903 (dollar_amount) — cash and cash equivalents as of June 30, 2025
• $561,681 (dollar_amount) — research and development expenses for six months ended June 30, 2025
• $3,000,000 (dollar_amount) — deferred revenue from Mayne Pharma

FAQ

Risk Factors

• Significant Cash Burn and Funding Needs [high — financial]: The company's cash and cash equivalents decreased to $3,737,903 as of June 30, 2025, from $5,606,863 at December 31, 2024. With no revenue generated, the company relies on its existing cash for operations and FDA processes, acknowledging uncertainty in raising additional capital if needed.
• FDA Approval Uncertainty [high — regulatory]: The company is pursuing FDA processes for its BCCNS product without further clinical trials. However, there is no assurance of success in obtaining regulatory approval, which is critical for future revenue generation.
• Dependence on Third-Party Formulations [medium — operational]: The company is engaged with Avior Bio, Inc. to create a novel formulation for itraconazole. Any delays or issues with Avior Bio's formulation development could significantly impact the company's product development timeline.
• Increasing Net Losses [high — financial]: The net loss for the six months ended June 30, 2025, was $1,292,788, an increase from $1,186,401 in the prior year. This widening loss, coupled with no revenue, highlights the company's ongoing financial challenges.
• Deferred Revenue Classification [medium — financial]: The company has $3.0 million in deferred revenue, representing royalties advanced by Mayne Pharma, classified as non-current. The timing and realization of this revenue are subject to contractual obligations and future sales performance.

Industry Context

The pharmaceutical industry, particularly in oncology and rare diseases, is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like INTI are focused on niche therapeutic areas, often relying on novel formulations or drug repurposing to address unmet medical needs. The competitive landscape involves both large pharmaceutical companies and smaller biotech firms, with success often hinging on clinical trial outcomes and FDA approvals.

Regulatory Implications

INTI's strategy to pursue FDA processes for its BCCNS product without further clinical trials presents a significant regulatory risk. The FDA's approval process is rigorous, and bypassing traditional clinical trial phases may face heightened scrutiny. Successful navigation of these regulatory pathways is paramount for the company's future commercialization efforts.

What Investors Should Do

1. Monitor cash runway and future funding announcements closely.
2. Evaluate the progress and potential success of the Avior Bio formulation development.
3. Assess the likelihood of FDA approval without additional clinical trials.

Key Dates

• 2025-06-30: Six months ended June 30, 2025 — Reported a net loss of $1,292,788 and had $3,737,903 in cash and cash equivalents, with no revenue generated.
• 2024-06-30: Six months ended June 30, 2024 — Reported a net loss of $1,186,401, indicating a widening loss in the current period.
• 2024-12-31: As of December 31, 2024 — Cash and cash equivalents were $5,606,863, showing a significant decrease by June 30, 2025.

Glossary

Deferred Revenue

Revenue that has been received by a company but has not yet been earned. It is recorded as a liability on the balance sheet. (In INTI's case, $3.0 million represents royalties advanced by Mayne Pharma, indicating a future revenue stream contingent on certain events or sales.)

BCCNS

Basal Cell Carcinoma Nevus Syndrome, a rare genetic disorder that increases the risk of developing various cancers, including basal cell carcinoma. (INTI is developing itraconazole for the treatment of BCCNS, representing a key focus of their drug development efforts.)

Formulation

The process of developing a specific dosage form for a drug, including its inactive ingredients and delivery method. (INTI is working with Avior Bio, Inc. to create a novel formulation of itraconazole, which is crucial for its efficacy and marketability.)

Cash Burn Rate

The rate at which a company spends its cash reserves, especially when it is not generating revenue. (INTI's declining cash position indicates a significant cash burn rate, highlighting the need for careful financial management and potential future fundraising.)

Year-Over-Year Comparison

Inhibitor Therapeutics, Inc. (INTI) reported a widening net loss for the six months ended June 30, 2025, compared to the same period in 2024, with losses increasing from $1,186,401 to $1,292,788. This occurred despite a slight decrease in general and administrative expenses, as research and development costs rose. The company's cash position also significantly deteriorated, falling from $5,606,863 at year-end 2024 to $3,737,903 as of June 30, 2025, reflecting a substantial cash burn with no revenue generation.

Filing Documents

• form10-q.htm (10-Q) — 431KB
• ex31-1.htm (EX-31.1) — 12KB
• ex31-2.htm (EX-31.2) — 12KB
• ex32-1.htm (EX-32.1) — 6KB
• ex32-2.htm (EX-32.2) — 6KB
• 0001641172-25-023465.txt ( ) — 2597KB
• inti-20250630.xsd (EX-101.SCH) — 20KB
• inti-20250630_cal.xml (EX-101.CAL) — 30KB
• inti-20250630_def.xml (EX-101.DEF) — 68KB
• inti-20250630_lab.xml (EX-101.LAB) — 197KB
• inti-20250630_pre.xml (EX-101.PRE) — 158KB
• form10-q_htm.xml (XML) — 289KB

Financial Statements (unaudited)

Financial Statements (unaudited) Condensed Balance Sheets as of June 30, 2025 and December 31, 2024 1 Condensed Statements of Operations for the three and six months ended June 30, 2025 and 2024 2 Condensed Statements of Stockholders' Equity for the three and six months ended June 30, 2025 and 2024 3 Condensed Statements of Cash Flows for the six months ended June 30, 2025 and 2024 4 Notes to Condensed Financial Statements 5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 12 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 15 Item 4.

Controls and Procedures

Controls and Procedures 15 Cautionary Note Regarding Forward Looking Statements 16

Other Information

Part II. Other Information Item 1

Legal Proceedings

Legal Proceedings 17 Item 1A.

Risk Factors

Risk Factors 17 Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 17 Item 3 Defaults upon Senior Securities 17 Item 4 Mine Safety Disclosures 17 Item 5 Other Information 17 Item 6. Exhibits 18

Signatures

Signatures 19 INHIBITOR THERAPEUTICS, INC. CONDENSED BALANCE SHEETS AS OF JUNE 30, 2025 AND DECEMBER 31, 2024 (Unaudited) June 30, 2025 December 31, 2024 ASSETS Current assets: Cash and cash equivalents $ 3,737,903 $ 5,606,863 Prepaid expenses and other assets 92,025 87,795 Total current assets 3,829,928 5,694,658 Operating lease right-of-use assets 77,734 — Total assets $ 3,907,662 $ 5,694,658 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 106,249 $ 15,896 Accrued expenses and other liabilities 7,725 693,722 Current operating lease obligations 25,987 — Total current liabilities 139,961 709,618 Deferred revenue 3,000,000 3,000,000 Operating lease obligations, less current portion 52,064 — Total liabilities 3,192,025 3,709,618 Commitments and contingencies (Note 6) — — Stockholders' equity: Series A preferred stock, $ 0.0001 par value; 500,000 shares authorized; no shares issued and outstanding at June 30, 2025 and December 31, 2024 — — Series B convertible, redeemable, preferred stock, $ 0.0001 par value; 7,246,377 shares authorized; no shares issued and outstanding at June 30, 2025 and December 31, 2024 — — Undesignated preferred stock, $ 0.0001 par value; 2,253,623 shares authorized; no shares issued and outstanding at June 30, 2025 and December 31, 2024 — — Preferred stock, value — — Common stock, $ 0.0001 par value; 500,000,000 shares authorized; 172,573,545 and 172,323,545 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 17,257 17,232 Additional paid-in capital 54,110,425 54,087,065 Accumulated deficit ( 53,412,045 ) ( 52,119,257 ) Total stockholders' equity 715,637 1,985,040 Total liabilities and stockholders' equity $ 3,907,662 $ 5,694,658 See notes to condensed financial statements 1 INHIBITOR THERAPEUTICS, INC. CONDENSED FOR THE THREE AND SIX MONT

View Full Filing

View this 10-Q filing on SEC EDGAR